A Randomized, Double-Blind, Controlled Trial Protocol for Therapeutic Neuroscience Education in Chronic Migraine Patients: A Clinical–Neurophysiological Combined Study Design
Matteo Castaldo(University of Parma), Alessandro Viganò(Sapienza University of Rome), Carlo Lovati(University of Milan), Giacomo Querzola(University of Milan), Chiara‐Camilla Derchi(Don Carlo Gnocchi Foundation), Simone Sarasso(University of Milan), Angela Comanducci, Paola Tiberio(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesca Baglio(University of Pavia), Tiziana Atzori(Don Carlo Gnocchi Foundation), Daniele Lovattini(University of Milan), Rita De Sanctis(Humanitas University)
Cited by 2
Related Papers
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
|The Lancet Oncology|2017|493
Challenges in Using Circulating miRNAs as Cancer Biomarkers
|BioMed Research International|2015|264
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
|The Lancet Neurology|2021|260
Hallmarks of primary headache: part 1 – migraine
|The Journal of Headache and Pain|2024|184
Functional changes in Duchenne muscular dystrophy
|Neurology|2011|178